Restricted accessResearch articleFirst published online 2023-09
Re: “A Multicenter Double-Blind,Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder
GolderS, LokeYK, WrightK, et al.Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review. PLoS Med, 2016; 13(9):e1002127; doi: 10.1371/journal.pmed.1002127.
2.
HealyD, Le NouryJ, JureidiniJ. Paediatric antidepressants: Benefits and risks. Int J Risk Saf Med, 2018; 30(1):1–7; doi: 10.3233/JRS-180746.
3.
SerrettiA, ChiesaA. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol, 2009; 29(3):259–266; doi: 10.1097/JCP.0b013e3181a5233f.
4.
StrawnJR, MoldauerL, HahnRD, et al.A multicenter double-blind, placebo-controlled trial of escitalopram in children and adolescents with generalized anxiety disorder. J Child Adolesc Psychopharmacol, 2023; 33(3):91–100; doi: 10.1089/cap.2023.0004.
